Racial disparities in late-stage prostate cancer: a SEER analysis 2005-2015.
Racial disparities in late-stage prostate cancer: a SEER analysis 2005-2015. Can J Urol. 2019 Oct;26(5):9946-9951 Authors: Rodriguez S, Sparks AD, Zhou H, Amdu RL, Lin J Abstract INTRODUCTION: To evaluate the impact of prostate cancer screening guidelines on different racial and ethnic populations. MATERIALS AND METHODS: Data was collected from the 2005-2015 Surveillance, Epidemiology, and End Results (SEER) program. Incidence of prostate cancer diagnosis was categorized and analyzed by stage, race/ethnicity, and age group. Appropriate univariate and multivariable statistical analysis was performed. RESULTS: The odds of being diagnosed with regional-stage prostate cancer in 2013-2015 were 1.3 times higher for black men, 1.3 times higher for Asian American/Pacific Islander (AAPI) men, and 1.2 times higher for white men when compared to 2005-2008. The odds of being diagnosed with distant-stage prostate cancer in 2013-2015 were 1.6 times higher for black men, 1.8 times higher for AAPI men, and 2.1 times higher for white men when compared to 2005-2008. In 2005-2008, 2009-2012, and 2013-2015 respectively, the odds of being diagnosed with distant-stage prostate cancer were 1.8 times higher, 1.7 times higher, and 1.4 times higher for black men compared to white men, and 1.5 times higher, 1.5 times higher, and 1.4 times higher for AAPI men compared to white men (all respective p
ConclusionApalutamide had manageable safety profile, without any DLT or any new safety signals, and favourable efficacy in Japanese mCRPC patients. Thus, it was ascertained to be an adequate dosage regimen in Japanese mCRPC patients.Trial registrationClinicalTrials.gov identifier: NCT02162836.
In this study, we report a novel 3D printed microfluidic device functionalized with anti-EpCAM (epithelial cell adhesion molecule) antibodies to isolate CTCs from human blood samples. A 3D printing technology was utilized with specially designed interior structures to fabricate a microfluidic device with high surface area and fluid flow manipulation, increasing the capture efficiency of tumor cells. These devices with the optimal flow rate (1 mL/h) and channel length (2 cm) were demonstrated to test three kinds of EpCAM positive cancer cell lines (MCF-7 breast cancer, SW480 colon cancer, and PC3 prostate cancer), and o...
This study demonstrated that FA-PMo4V8 is simply designed and accurate in colorimetric detection of urinary sarcosine, which could be useful for clinical applications.Graphical Abstract
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Pirus Ghadjar, Thomas Wiegel
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Elise De Bleser, Piet Ost
(Intermountain Medical Center) Intermountain research team identified 87 patients who were part of the Intermountain INSPIRE Registry and had developed prostate cancer. These patients were also tested for plasma levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are two common omega-3 fatty acids.
Authors: Montgomery B PMID: 31730580 [PubMed - in process]
Publication date: Available online 15 November 2019Source: Meta GeneAuthor(s): Berjas Abumsimir, Mohammed Mrabti, Abdelilah Laraqui, Ahmed Ameur, Saad Ibnsouda Koraishi, Mohammed Mzibrie, Mohammed Nabil Benchekroun, Hlima Bessi, Ikram Tiabi, Ihsan Almahasneh, Moulay Mustapha EnnajiAbstractThe home box transcription factor gene (HOXB13) plays a certain role in human development and prostate tumorgenesis. Genetic alterations of HOXB13 help to explore the suspected role in prostate cancer. To determine the prevalence and clinical correlates of high-frequent mutational events in home box transcription factor (HOXB13); DNA samp...
Immunotherapy drugs have so far produced underwhelming results in prostate cancer. Now a team of researchers may have figured out why and how to make these drugs work for prostate cancer patients.
LEN GOODMAN, best known for being a head judge on TV dance competition Strictly Come Dancing, underwent a secret health battle while on the show that not even the BBC knew about at the time. The star was diagnosed with prostate cancer.